Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Seok Jae Huh, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Won-Sik Lee, Yoojin Lee, MD PhD, Ho Sup Lee, MD

Blood (2018) 132 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2018-99-119473

Published: 2018

Journal Articles

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Ji Hyun Lee, MD PhD, Sung Yong Oh, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho Sup Lee, MD

Blood (2017) 130 (Supplement 1): 4142.

https://doi.org/10.1182/blood.V130.Suppl_1.4142.4142

Published: 2017

Journal Articles

Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Taeyun Kim, MD, Ho Sup Lee, MD, Jee-Yeong Jeong, PhD, Jae-Cheol Jo, MD PhD, Won-Sik Lee, MD PhD, Ho-Jin Shin, MD, Ji Hyun Lee, MD PhD

Blood (2017) 130 (Supplement 1): 4158.

https://doi.org/10.1182/blood.V130.Suppl_1.4158.4158

Published: 2017

Journal Articles

Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy

Ji Hyun Lee, MD PhD, Sung Yong Oh, Ho Sup Lee, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho-Jin Shin, MD

Blood (2017) 130 (Supplement 1): 2856.

https://doi.org/10.1182/blood.V130.Suppl_1.2856.2856

Published: 2017

Journal Articles

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

Blood (2017) 130 (Supplement 1): 2840.

https://doi.org/10.1182/blood.V130.Suppl_1.2840.2840

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

the Effect of Erythropoiesis-Stimulating Agent on the Management of Chemotherapy-Induced Anemia and Tumor Growth in Diffuse Large B-Cell Lymphoma Patients

Lee Chun Park, MD, Ho Sup Lee, MD, Da Jung Kim, MD, Jee-yeong Jeong, PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD, Sung Yong Oh, Young Rok Do, MD PhD

Blood (2017) 130 (Supplement 1): 5209.

https://doi.org/10.1182/blood.V130.Suppl_1.5209.5209

Published: 2017

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, MBBS, MD, Asher A. Chanan-Khan, MD, Noemi Horvath, FRACP, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, PhD, Pieter Sonneveld, MDPhD, Jordan Schecter, Vania T M Hungria, MD PhD

Blood (2017) 130 (Supplement 1): 1852.

https://doi.org/10.1182/blood.V130.Suppl_1.1852.1852

Published: 2017

Journal Articles

Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2017) 130 (Supplement 1): 4088.

https://doi.org/10.1182/blood.V130.Suppl_1.4088.4088

Published: 2017

Journal Articles

A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial

Byeong-Bae Park, Won Seog Kim, Cheolwon Suh, Dok Hyun Yoon, Jong-Ho Won, Deok-Hwan Yang, Young-Rok Do, Won Sik Lee, Jeong-A Kim, Min Kyoung Kim, Jae-Cheol Jo, MD PhD, Youngil Koh, MD PhD

Blood (2016) 128 (22): 1823.

https://doi.org/10.1182/blood.V128.22.1823.1823

Published: 2016

Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3313.

https://doi.org/10.1182/blood.V128.22.3313.3313

Published: 2016

Journal Articles

LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR

Hawk Kim, Sook-Kyoung Heo, PhD, Eui-Kyu Noh, PhD, Gi-Dong Gwon, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD PhD, Jinny Park

Blood (2016) 128 (22): 4546.

https://doi.org/10.1182/blood.V128.22.4546.4546

Published: 2016

Journal Articles

The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, MD PhD, Dok Hyun Yoon, Chang-Ki Min, Sang Kyun Sohn, MD, PhD, Chul Won Choi, Ho Sup Lee, Hyo Jung Kim, Ho-Jin Shin, MD PhD, Soo-Mee Bang, Sung-Soo Yoon, MD PhD, Seong Kyu Park, Ho-Young Yhim, Min Kyoung Kim, MD, Jae-Cheol Jo, MD PhD, Yeung-Chul Mun, Jae-Hoon Lee, Jin Seok Kim, MD PhD

Blood (2016) 128 (22): 4445.

https://doi.org/10.1182/blood.V128.22.4445.4445

Published: 2016

Journal Articles

Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Cheolsu Kim, MD, Ho Sup Lee, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Sung Yong Oh, MD, Won Sik Lee, MD, Jee-yeong Jeong, PhD

Blood (2016) 128 (22): 4220.

https://doi.org/10.1182/blood.V128.22.4220.4220

Published: 2016

NARROW

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

the Effect of Erythropoiesis-Stimulating Agent on the Management of Chemotherapy-Induced Anemia and Tumor Growth in Diffuse Large B-Cell Lymphoma Patients

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR

The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only